Hypoglycemic and hypolipemic effects of a new lecithin formulation of bergamot polyphenolic fraction: A double blind, randomized, placebo-controlled study 

In a randomized, placebo-controlled study, 237 patients suffering from a combination of hypercholesterolemia, hyperlipidemia and hyperglycemia received 0, 500 or 1,000 mg/day of bergamot extract (23–27% flavonoids by weight) for 30 days. Patients receiving bergamot extract exhibited reductions in LDL-C of 23–27% (at 500 mg/day) and 33–39% (at 1,000 mg/day). Similar reductions were observed in triglycerides. HDL-C levels increased by 17–26% (at 500 mg/day) and 30–39% (at 1,000 mg/day). 

References:

Mollace, V., Scicchitano, M., Paone, S., Casale, F., Calandruccio, C., Gliozzi, M., Musolino, V., Carresi, C., Maiuolo, J., Nucera, S., Riva, A., Allegrini, P., Ronchi, M., Petrangolini, G., & Bombardelli, E. (2019). Hypoglycemic and Hypolipemic Effects of a New Lecithin Formulation of Bergamot Polyphenolic Fraction: A Double Blind, Randomized, Placebo- Controlled Study. Endocrine, metabolic & immune disorders drug targets, 19(2), 136–143. https://doi.org/10.2174/1871530319666181203151513